এই ওষুধে সাশ্রয় করুন
একই সক্রিয় উপাদানের অন্যান্য ব্র্যান্ড
এই ব্র্যান্ডগুলোতে একই সক্রিয় উপাদান আছে (Methimazole). Strength ও ফর্ম আলাদা হতে পারে — পরিবর্তনের আগে আপনার ডাক্তার বা ফার্মাসিস্টের সাথে বিকল্প ওষুধটি নিশ্চিত করে নিন।
ইঙ্গিত ও ব্যবহার
Methiroid-5 এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Methimazole is administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8 hour intervals.Adults: The initial daily dosage is 15 mg for mild hyperthyroidism, 30 to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8 hour intervals. The maintenance dosage is 5 to 15 mg daily.Pediatric: Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8 hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.Use in children & adolescents: Because of post-marketing reports of severe liver injury in pediatric patient treated with propylthiouracil, Methimazole is the preferred choice when an antithyroid drug is required for a pediatric patient.
পার্শ্বপ্রতিক্রিয়া
Common: Skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.Rare: Agranulocytosis, granulocytopenia, thrombocytopenia and aplastic anemia, drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Congenital Malformations: Methiroid readily crosses the placental membranes and can cause fetal harm, particularly when administered in the first trimester of pregnancy. If Methiroid is used during pregnancy or if the patient becomes pregnant while taking Methiroid, the patient should be warned of the potential hazard to the fetus. Since some congenital defects have been reported in offspring of patients treated with Methiroid, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy. If Methiroid is used, the lowest possible dose to control the disease should be given.Agranulocytosis: Agranulocytosis is potentially a life-threatening adverse reaction of Methiroid therapy. Patients should be instructed to immediately report to their physicians if any symptoms suggestive of agranulocytosis, such as fever or sore throat occur. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur. The drug should be discontinued in the presence of agranulocytosis, aplastic anemia (pancytopenia), ANCA-positive vasculitis, hepatitis, or exfoliative dermatitis and the patient’s bone marrow indices should be monitored.Liver Toxicity: Although there have been reports of hepatotoxicity associated with Methiroid, the risk of hepatotoxicity appears to be less with Methiroid than with propylthiouracil, especially in the pediatric population. Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.Hypothyroidism: Methiroid can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, Methiroid can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy. Because Methiroid may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures. Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of Methiroid should be employed.
নিষেধাজ্ঞা
Methimazole is contraindicated in the presence of hypersensitivity to the drug or any of the other product components.